- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Do | OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program | 326 | Newsfile | FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize... ► Artikel lesen | |
| Di | OS Therapies: OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing | 327 | Newsfile | Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in... ► Artikel lesen | |
| 09.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | OS Therapies Reports Strong Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 08.09. | OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 359 | Newsfile | 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from... ► Artikel lesen | |
| 02.09. | OS Therapies: OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance | 723 | Newsfile | Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors... ► Artikel lesen | |
| 21.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | OS Therapies Secures Up To $10 Million Debt Financing Against U.K. Tax Refunds And R&D Credits | 1 | pulse2.com | ||
| 17.08. | OS Therapies GAAP EPS of -$0.20 misses by $0.03 | 1 | Seeking Alpha | ||
| 17.08. | OS Therapies: OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates | 967 | Newsfile | Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closingFDA Type C Statistical... ► Artikel lesen | |
| 14.08. | OS Therapies Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | OS Therapies: OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma | 671 | Newsfile | Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation... ► Artikel lesen | |
| 12.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Roth/MKM initiates OS Therapies stock with buy on therapy outlook | 3 | Investing.com | ||
| 08.07. | OS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program | 690 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 06.07. | OS Therapies: OS Therapies Third Quarter 2026 Corporate Outlook | 928 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 02.07. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | OS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of Directors | 1.044 | Newsfile | Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American:... ► Artikel lesen | |
| 30.06. | OS Therapies: OS Therapies Provides U.S. Regulatory Update | 1.000 | Newsfile | Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA SubmissionSeeking to align FDA with MHRA & EMA on 3-year overall... ► Artikel lesen |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| PALATIN TECHNOLOGIES | 10,900 | +0,37 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,927 | -0,11 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -1,48 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,568 | +0,02 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| IMMUNIC | 9,010 | -2,83 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,050 | +1,94 % | Phio Pharmaceuticals Corp.: Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma | Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,750 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 6,510 | +0,71 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,038 | -0,59 % | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | ||
| ROCKET PHARMACEUTICALS | 2,940 | 0,00 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| VOYAGER THERAPEUTICS | 2,664 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,820 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.